Innoviva Inc
$ 23.92
-1.32%
20 Apr - close price
- Market Cap 1,809,177,000 USD
- Current Price $ 23.92
- High / Low $ 24.45 / 23.81
- Stock P/E 7.35
- Book Value 15.71
- EPS 3.30
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.07 %
- ROE 0.29 %
- 52 Week High 25.14
- 52 Week Low 16.52
About
Innoviva, Inc. is dedicated to the development and commercialization of pharmaceutical products. The company is headquartered in Burlingame, California.
Analyst Target Price
$33.20
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-04 | 2025-11-05 | 2025-08-06 | 2025-05-06 | 2025-02-26 | 2024-11-06 | 2024-07-31 | 2024-05-08 | 2024-02-29 | 2023-11-01 | 2023-08-02 | 2023-05-09 |
| Reported EPS | 1.944 | 0.3846 | 0.77 | -0.7429 | 0.26 | 0.12 | -0.55 | 0.46 | 0.76 | 0.98 | 0.02 | 0.42 |
| Estimated EPS | 0.574 | 0.4 | 0.5 | 0.33 | 0.41 | 0.27 | 0.24 | 0.17 | 0.23 | 0.27 | 0.26 | 0.23 |
| Surprise | 1.37 | -0.0154 | 0.27 | -1.0729 | -0.15 | -0.15 | -0.79 | 0.29 | 0.53 | 0.71 | -0.24 | 0.19 |
| Surprise Percentage | 238.676% | -3.85% | 54% | -325.1212% | -36.5854% | -55.5556% | -329.1667% | 170.5882% | 230.4348% | 262.963% | -92.3077% | 82.6087% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.43 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|
| Payment Date | None | None | None | None | None | None |
| Amount | $0.25 | $0.25 | $0.25 | $0.25 | $0.25 | $5.571428571 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: INVA
2026-04-18 08:10:06
Innoviva, Inc. (NASDAQ:INVA) has received a consensus "Moderate Buy" rating from seven brokerages, with an average 12-month price target of $34.80. The biopharmaceutical company recently reported strong earnings, with $1.94 EPS against a $0.34 consensus and revenue of $114.6 million, significantly beating analyst estimates. Innoviva maintains a strong financial position with substantial institutional ownership and healthy liquidity ratios.
2026-04-16 06:38:59
Innoviva (NASDAQ:INVA) stock has surpassed its 200-day moving average, trading at $23.92 with increased volume, indicating a positive technical trend. Analysts have a consensus "Moderate Buy" rating with an average target price of $34.80. The company reported strong financial results, including significant quarterly earnings beat and robust margins, suggesting solid fundamentals.
2026-04-12 09:40:07
The article provides a technical analysis and stock price forecast for Innoviva Inc. (INVA), indicating a "Strong Buy" consensus based on various technical indicators and moving averages. It details momentum indicators like MACD and RSI, support and resistance levels, and Innoviva's performance relative to its 200-day moving average, which suggests a long-term bullish trend.
2026-04-10 20:26:00
This article from Stock Traders Daily analyzes Innoviva Inc. (NASDAQ: INVA), highlighting strong sentiment across all horizons and an exceptional risk-reward short setup. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal analysis indicating strong support and resistance levels for the stock.
2026-04-08 15:10:30
Cantor Fitzgerald has reiterated its Buy rating for Innoviva (INVA.US) and maintained its target price at $32. This indicates a continued positive outlook from the firm regarding the company's stock performance.
2026-04-08 12:12:11
Cantor Fitzgerald has reiterated an Overweight rating and $32.00 price target for Innoviva Inc. (NASDAQ:INVA), highlighting the company's strong foundational stability driven by its recurring royalty business, which generated approximately $250 million in 2025. The firm noted Innoviva's impressive financial health with a 75% gross profit margin and a 14.64 current ratio, along with aggressive capital redeployment into its Innoviva Specialty Therapeutics segment and strategic investments. BTIG also initiated coverage with a Buy rating and a $35.00 price target, anticipating significant benefits from royalty rights for COPD and asthma therapies through 2030.
